Sectors
ADMA
ADMA Biologics, Inc.
9.39
2 x 6.44
2 x 11.52
bid
ask
+
0.05
0.54%
2 @ 04:50 AM
9.50 +0.11 (1.17%)
| Ytd | -48.52% | |
| 1y | -45.60% |
9.22
day range
9.47
7.21
52 week range
20.46
| Open | 9.33 | Prev Close | 9.34 | Low | 9.22 | High | 9.47 | Mkt Cap | 2.10B |
| Vol | 1.76M | Avg Vol | 2.88M | EPS | 0.70 | P/E | 13.41 | Forward P/E | 9.56 |
| Beta | 0.74 | Short Ratio | 8.53 | Inst. Own | 93.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 9.06 | 200-d Avg | 12.80 | 1yr Est | 17.00 |
ADMA News
gurufocus.com
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Du
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Du
prnewswire.com
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Du
PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announc
newsfilecorp.com
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potenti
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recogn
benzinga.com
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to
benzinga.com
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst